[197] Bernau C, Riester M, Boulesteix AL, Parmigiani G, Huttenhower C, Waldron L, Trippa L.
Cross-
study validation for the assessment of prediction algorithms.
Bioinformatics 30; i105–i112 Jun
2014. PMCID: PMC4058929.
[198] Mazzola E, Chipman J, Cheng SC, Parmigiani G.
Recent BRCAPRO upgrades significantly improve
calibration.
Cancer Epidemiol Biomarkers Prev Jun 2014. PMCID:PMC4119541.
[199] Zhao SD, Parmigiani G, Huttenhower C, Waldron L.
Ms-o-menos: a simple sign averaging method
for discrimination in genomic data analysis.
Bioinformatics 30(21); 3062–9 Jul 2014. PMCID:
PMC4201155.
[200] Braun D, Gorfine M, Parmigiani G.
Misreported family histories and underestimation of risk.
J
Clin Oncol 32(32); 3682–3 Sep 2014.
[201] Ahern C, Shih YC, Dong W, Parmigiani G, Shen Y. Cost-effectiveness of alternative strategies
for integrating mri into breast cancer screening for women at high risk. British Journal of Cancer
111(8); 1542–51 2014. PMCID: PMC4200098.
[202] Liu D, Parmigiani G, Caffo B. Screening for differentially expressed genes: Are multilevel models
helpful? Journal of Biometrics Biostatistics 5(2); 192 2014.
[203] Rashid NU, Sperling AS, Bolli N, Wedge DC, Loo PV, Tai YT, Shammas MA, Fulciniti M, Samur
MK, Richardson PG, Magrangeas F, Minvielle S, Futreal PA, Anderson KC, Avet-Loiseau H,
Campbell PJ, Parmigiani G, Munshi NC.
Differential and limited expression of mutant alleles in
multiple myeloma.
Blood 124(20); 3110–7 Sep 2014. PMCID: PMC4231420.
[204] Parmigiani G, Boca S, Ding J, Trippa. L. Statistical tools and r software for cancer driver proba-
bilities. Methods Mol Biol 1101; 113–34 2014.
[205] Trippa L, Wen PY, Parmigiani G, Berry DA, Alexander BM.
Combining progression-free survival
and overall survival as a novel composite endpoint for glioblastoma trials.
Neuro Oncol Jan 2015.
[206] Tomasetti C, Marchionni L, Nowak MA, Parmigiani G, Vogelstein B.
Only three driver gene
mutations are required for the development of lung and colorectal cancers.
Proc Natl Acad Sci U
S A 112; 118–123 Jan 2015. PMCID: PMC4291633.
[207] Wang C, Dominici F, Parmigiani G, Zigler CM.
Accounting for uncertainty in confounder and effect
modifier selection when estimating average causal effects in generalized linear models.
Biometrics
Apr 2015.
[208] Hatchi E, Skourti-Stathaki K, Ventz S, Pinello L, Yen A, Kamieniarz-Gdula K, Dimitrov S, Patha-
nia S, McKinney KM, Eaton ML, Kellis M, Hill SJ, Parmigiani G, Proudfoot NJ, Livingston
DM.
BRCA1 recruitment to transcriptional pause sites is required for R-loop-driven DNA damage
repair.
Mol Cell 57; 636–647 Feb 2015.
[209] Trippa L, Waldron L, Huttenhower C, Parmigiani. G. Bayesian nonparametric cross-study valida-
tion of prediction methods. Ann Appl Stat 9; 402–428 2015.
[210] Mazzola E, Blackford A, Parmigiani G, Biswas S.
Recent enhancements to the genetic risk
prediction model BRCAPRO.
Cancer Inform 14; 147–157 2015. PMCID: PMC4428390.
19
[211] Tyekucheva S, Martin NE, Stack EC, Wei W, Vathipadiekal V, Waldron L, Fiorentino M, Lis RT,
Stampfer MJ, Loda M, Parmigiani G, Mucci LA, Birrer M.
Comparing platforms for messenger
RNA expression profiling of archival formalin-fixed, paraffin-embedded tissues.
J Mol Diagn 17;
374–381 Jul 2015.
[212] Venturini S, Dominici F, Parmigiani G. Generalized quantile treatment effect: A flexible bayesian
approach using quantile ratio smoothing. Bayesian Analysis 10; 523–552 2015.
[213] Gerke TA, Martin NE, Ding Z, Nuttall EJ, Stack EC, Giovannucci E, Lis RT, Stampfer MJ, Kantoff
PW, Parmigiani G, Loda M, Mucci LA. Evaluating a 4-marker signature of aggressive prostate
cancer using time-dependent auc. The Prostate 75(16); 1926–33 2015. Doi: 10.1002/pros.23090.
[214] Munshi N, Bolli N, Minvielle S, Anderson KC, Parmigiani G, P. Campbell HAL. Next generation
sequencing in multiple myeloma. Clinical Lymphoma Myeloma and Leukemia 15(Supplement 3);
e2–e3 2015. Http://doi.org/10.1016/j.clml.2015.08.004.
[215] Zhang Y, Trippa L, Parmigiani G.
Optimal bayesian adaptive trials when treatment efficacy
depends on biomarkers.
Biometrics doi: 10.1002/pros.23090 Nov 2015.
[216] Biswas S, Atienza P, Chipman J, Blackford AL, Arun B, Hughes K, Parmigiani G.
A two-stage
approach to genetic risk assessment in primary care.
Breast Cancer Res Treat 155; 375–383 Jan
2016.
[217] Mucci LA, Hjelmborg JB, Harris JR, Czene K, Havelick DJ, Scheike T, Graff RE, Holst K, Mller
S, Unger RH, McIntosh C, Nuttall E, Brandt I, Penney KL, Hartman M, Kraft P, Parmigiani G,
Christensen K, Koskenvuo M, Holm NV, Heikkil K, Pukkala E, Skytthe A, Adami HO, Kaprio J,
of Cancer (NorTwinCan) Collaboration NTS.
Familial risk and heritability of cancer among twins
in nordic countries.
JAMA 315; 68–76 Jan 2016.
[218] Marabelli M, Cheng SC, Parmigiani G.
Penetrance of ATM gene mutations in breast cancer: A
meta-analysis of different measures of risk.
Genet Epidemiol Apr 2016.
[219] Waldron L, Riester M, Ramos M, Parmigiani G, Birrer M.
The doppelgnger effect: Hidden
duplicates in databases of transcriptome profiles.
J Natl Cancer Inst 108 Nov 2016.
[220] Harrington D, Parmigiani G.
I-SPY 2–a glimpse of the future of phase 2 drug development?
N
Engl J Med 375; 7–9 Jul 2016.
[221] Barber LE, Gerke TA, Markt SC, Parmigiani G, Mucci LA. A family affair: Prostate cancer risk
and family history of breast or prostate cancer. Cancer Research 76(14); 2543 2016.
[222] de Vito R, Bellio R, Trippa L, Parmigiani G. Multi-study factor analysis. arXivorg 2016.
[223] Cefalu M, Dominici F, Arvold N, Parmigiani G. Model averaged double robust estimation. Bio-
metrics 2016.
[224] Mosen-Ansorena D, Bashford-Rogers R, Bolli N, Minvielle S, Magrangeas F, Anderson KC, Avet-
Loiseau H, Parmigiani G, Munshi NC. RNA-seq de novo assembly of clonal immunoglobulin
rearrangements identifies interesting biology and uncovers prognostic features in multiple myeloma.
Blood 128(22); 195 2016.
20